Intellia Therapeutics (NTLA) Stock Forecast, Price & News

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NTLA shares.
View NTLA analyst ratings or view top-rated stocks.

18 Wall Street research analysts have issued 1-year target prices for Intellia Therapeutics' shares. Their NTLA share price forecasts range from $40.00 to $120.00. On average, they predict the company's share price to reach $80.18 in the next twelve months. This suggests a possible upside of 152.4% from the stock's current price.
View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts.

Intellia Therapeutics' stock was trading at $34.89 at the beginning of 2023. Since then, NTLA stock has decreased by 9.0% and is now trading at $31.76.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our NTLA earnings forecast.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) released its earnings results on Thursday, August, 3rd. The company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by $0.08. The company earned $13.59 million during the quarter, compared to analysts' expectations of $12.08 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 41.64% and a negative net margin of 854.92%. The firm's revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.33) EPS.

ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), Horizon Kinetics Medical ETF (MEDX), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA) and Franklin Genomic Advancements ETF (HELX).

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTLA stock can currently be purchased for approximately $31.76.

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $2.81 billion and generates $53.04 million in revenue each year. The company earns $-474,190,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis.

The company employs 598 workers across the globe.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.